Security
Inspire Medical Systems, Inc. · INSP
INSPNYSECommon stockCurrentCIK 1609550Updated Nov 3, 2026
INSP price & chart
Loading TradingView…
NYSE:INSP on TradingView ↗About the company
Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first FDA, EU MDR and PDMA-approved neurostimulation technology of its kind that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. For additional information about Inspire, please visit www.inspiresleep.com.
In the news
Inspire Medical Systems, Inc. Announces Approval of New Hypoglossal Nerve Stimulation CPT® Codes by the AMA Editorial Panel ↗
2-DAY DEADLINE ALERT: $42.04 Stock Drop at Inspire Medical Systems (INSP) Triggers Securities Fraud Lawsuit Over Concealed Medicare Billing Software Failures & Inspire V Inventory Glut News provided by Hagens Berman Sobol Shapiro LLP Jan 03, 2026, 09:00 ET Share this article Share to X Share this ar ↗
5-DAY DEADLINE ALERT: $42.04 Stock Drop at Inspire Medical Systems (INSP) Triggers Securities Fraud Lawsuit Over Concealed Medicare Billing Software Failures & Inspire V Inventory Glut News provided by Hagens Berman Sobol Shapiro LLP Jan 01, 2026, 09:00 ET Share this article Share to X Share this ar ↗
Seeking Alpha
Inspire Medical Systems, Inc. (INSP) Q3 2026 Earnings Call Transcript ↗
Inspire Medical Systems Non-GAAP EPS of $0.14 beats by $0.05, revenue of $206.7M beats by $2.39M ↗
Inspire Medical Systems Q3 2026 Earnings Preview ↗
SEC disclosures
Inspire Medical Systems, Inc. files 8-K: Material Event ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
4 filing
4 filing
4 filing
Show 5 more recent filings
SCHEDULE 13G/A - filed by Soleus Capital Master Fund, L.P. regarding Inspire Medical Systems, Inc.
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
SCHEDULE 13G/A - filed by VANGUARD PORTFOLIO MANAGEMENT LLC regarding Inspire Medical Systems, Inc.
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 807,716,000Source | 796,194,000Source | 925,993,000Source | 802,193,000Source | 728,389,000Source | 911,376,000Source | 730,809,000Source | 685,842,000Source | 907,317,000Source | 808,383,000Source | 676,811,000Source | 564,876,000Source |
| Property, Plant and Equipment, NetUSD | 91,506,000Source | 67,447,000Source | 104,330,000Source | 85,274,000Source | 61,701,000Source | 100,692,000Source | 77,175,000Source | 52,281,000Source | 97,872,000Source | 71,925,000Source | 39,984,000Source | 17,249,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 112,845,000Source | 147,512,000Source | 127,761,000Source | 106,927,000Source | 188,035,000Source | 98,932,000Source | 53,882,000Source | 175,416,000Source | 104,813,000Source | 150,150,000Source | 185,537,000Source | 441,592,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 107,989,000Source | 89,743,000Source | 103,340,000Source | 137,687,000Source | 79,716,000Source | 105,088,000Source | 92,628,000Source | 72,333,000Source | 119,692,000Source | 93,068,000Source | 89,884,000Source | 61,228,000Source |
| Inventory, NetUSD | 141,777,000Source | 67,432,000Source | 170,451,000Source | 121,633,000Source | 59,025,000Source | 166,235,000Source | 99,727,000Source | 48,974,000Source | 145,293,000Source | 80,118,000Source | 33,885,000Source | 11,886,000Source |
| Assets, CurrentUSD | 586,489,000Source | 582,520,000Source | 608,674,000Source | 573,189,000Source | 607,160,000Source | 566,819,000Source | 571,679,000Source | 572,214,000Source | 583,652,000Source | 630,806,000Source | 593,739,000Source | 530,032,000Source |
| Operating Lease, Right-of-Use AssetUSD | 24,070,000Source | 21,811,000Source | 22,599,000Source | 24,524,000Source | 22,189,000Source | 23,068,000Source | 24,972,000Source | 22,248,000Source | 23,532,000Source | 23,314,000Source | 22,667,000Source | 6,880,000Source |
| Other Assets, NoncurrentUSD | 17,298,000Source | 10,991,000Source | 18,328,000Source | 9,376,000Source | 10,995,000Source | 17,250,000Source | 12,152,000Source | 11,296,000Source | 17,264,000Source | 11,343,000Source | 11,278,000Source | 10,715,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 141,256,000Source | 99,632,000Source | 100,411,000Source | 124,379,000Source | 90,318,000Source | 119,036,000Source | 95,066,000Source | 96,818,000Source | 126,157,000Source | 118,688,000Source | 104,297,000Source | 68,868,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 29,000Source | 30,000Source | 29,000Source | 29,000Source | 30,000Source | 29,000Source | 29,000Source | 30,000Source | 29,000Source | 30,000Source | 30,000Source | 29,000Source |
| Additional Paid in CapitalUSD | 948,374,000Source | 1,021,970,000Source | 983,670,000Source | 969,903,000Source | 983,791,000Source | 950,449,000Source | 924,409,000Source | 944,298,000Source | 927,159,000Source | 981,043,000Source | 917,107,000Source | 820,335,000Source |
| Retained Earnings (Accumulated Deficit)USD | -282,582,000Source | -327,138,000Source | -157,472,000Source | -292,514,000Source | -345,635,000Source | -157,786,000Source | -288,922,000Source | -355,428,000Source | -146,492,000Source | -291,914,000Source | -345,423,000Source | -324,270,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 639,000Source | 1,700,000Source | -645,000Source | 396,000Source | -115,000Source | -352,000Source | 227,000Source | 124,000Source | 464,000Source | 536,000Source | 800,000Source | -86,000Source |
| Stockholders' Equity Attributable to ParentUSD | 666,460,000Source | 696,562,000Source | 825,582,000Source | 677,814,000Source | 638,071,000Source | 792,340,000Source | 635,743,000Source | 589,024,000Source | 781,160,000Source | 689,695,000Source | 572,514,000Source | 496,008,000Source |
| Liabilities and EquityUSD | 807,716,000Source | 796,194,000Source | 925,993,000Source | 802,193,000Source | 728,389,000Source | 911,376,000Source | 730,809,000Source | 685,842,000Source | 907,317,000Source | 808,383,000Source | 676,811,000Source | 564,876,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 110,843,000Source | 74,264,000Source | 71,182,000Source | 93,359,000Source | 65,657,000Source | 89,418,000Source | 63,470,000Source | 72,172,000Source | 96,055,000Source | 88,501,000Source | 78,105,000Source | 61,186,000Source |
| Operating Lease, Liability, CurrentUSD | 2,274,000Source | 109,000Source | — | 2,150,000Source | — | — | 2,035,000Source | — | 2,157,000Source | 1,754,000Source | 0Source | 1,336,000Source |
| Operating Lease, Liability, NoncurrentUSD | 30,302,000Source | 25,218,000Source | 29,093,000Source | 30,909,000Source | 24,512,000Source | 29,552,000Source | 31,488,000Source | 24,500,000Source | 29,998,000Source | 30,039,000Source | 24,846,000Source | 7,536,000Source |
| Other Liabilities, NoncurrentUSD | 111,000Source | 150,000Source | 136,000Source | 111,000Source | 149,000Source | 66,000Source | 108,000Source | 146,000Source | 104,000Source | 148,000Source | 1,346,000Source | 146,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 51,603,000Source | 39,338,000Source | 44,080,000Source | 40,197,000Source | 32,036,000Source | 47,569,000Source | 34,333,000Source | 28,370,000Source | 59,490,000Source | 49,814,000Source | 39,266,000Source | 34,339,000Source |
| Short-term InvestmentsUSD | 209,747,000Source | 263,475,000Source | 192,923,000Source | 193,968,000Source | 251,629,000Source | 184,902,000Source | 315,307,000Source | 265,945,000Source | 203,455,000Source | 295,396,000Source | 274,838,000Source | 9,821,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 5,110,000Source | 3,044,000Source | 13,957,000Source | 6,550,000Source | 2,846,000Source | 1,858,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | 29,500,000Source | 28,200,000Source | 31,200,000Source | 41,700,000Source | 30,689,000Source | 31,056,000Source | 130,259,000Source | 116,007,000Source | 82,470,000Source | 51,970,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 20,942,000Source | 19,609,000Source | 65,175,000Source | 46,233,000Source | 21,999,000Source | -5,345,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 7,132,000Source | -9,517,000Source | -3,747,000Source | 604,000Source | 9,296,000Source | 14,355,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | 1,009,000Source | 0Source | -88,751,000Source | -13,000Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 12,849,000Source | -6,703,000Source | 116,976,000Source | 130,246,000Source | 24,653,000Source | 11,569,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -11,249,000Source | -1,553,000Source | 21,446,000Source | -113,122,000Source | -294,822,000Source | -19,596,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 9,726,000Source | 8,407,000Source | 38,499,000Source | 39,123,000Source | 23,629,000Source | 9,096,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 7,591,000Source | 19,192,000Source | 23,044,000Source | 5,165,000Source | 17,158,000Source | 43,000Source |
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | 0Source | 75,009,000Source | 175,019,000Source | 75,000,000Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -7,482,000Source | -87,760,000Source | -183,449,000Source | -52,393,000Source | 13,950,000Source | 235,077,000Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 24,500,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -5,881,000Source | -96,268,000Source | -45,337,000Source | -35,387,000Source | -256,055,000Source | 227,125,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 112,845,000Source | 147,512,000Source | 127,761,000Source | 106,927,000Source | 98,932,000Source | 53,882,000Source | 104,813,000Source | 150,150,000Source | 185,537,000Source | 441,592,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 16,000Source | 0Source | 137,000Source | 22,000Source | 0Source | 2,321,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 8,324,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | 1,000Source | -252,000Source | -310,000Source | -118,000Source | 164,000Source | 75,000Source |
| Additional Financial Items | ||||||||||||
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual AmountUSD | — | — | 0Source | 0Source | — | 4,000,000Source | 0Source | 0Source | 4,046,000Source | 0Source | 400,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | 3,619,000Source | 1,829,000Source | 2,801,000Source | 1,260,000Source | 13,691,000Source | 1,167,000Source | -79,725,000Source | 4,944,000Source | 1,247,000Source | 613,000Source |
| InterestExpenseNonoperatingUSD | — | — | 11,000Source | 0Source | — | 4,000Source | — | — | 137,000Source | 22,000Source | — | — |
| Inventory Write-downUSD | — | — | — | — | — | — | — | — | — | — | — | 1,800,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 9,932,000Source | 18,497,000Source | 314,000Source | -3,592,000Source | -11,294,000Source | 2,992,000Source | 145,422,000Source | 53,509,000Source | -21,153,000Source | -44,881,000Source |
| Nonoperating Income (Expense)USD | — | — | 3,907,000Source | 6,008,000Source | — | 984,000Source | — | 5,644,000Source | 14,743,000Source | 22,370,000Source | 20,365,000Source | 3,324,000Source |
| Operating Costs and ExpensesUSD | — | — | 183,084,000Source | 156,475,000Source | 171,973,000Source | 185,730,000Source | 178,030,000Source | 172,093,000Source | 727,802,000Source | 643,735,000Source | — | — |
| Operating ExpensesUSD | — | — | — | 156,475,000Source | — | — | — | — | — | — | 568,494,000Source | 389,333,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 1,400,000Source | 1,040,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -66,000Source | 118,000Source | -110,000Source | -3,498,000Source | -226,000Source | 578,000Source | -2,656,000Source | -855,000Source | -195,000Source | -49,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 243,801,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 109,000Source | 6,441,000Source | 9,595,000Source | 22,167,000Source | 25,809,000Source | 12,081,000Source |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | 302,000Source | 1,556,000Source | — | -22,000Source | -814,000Source | -9,000Source | 224,000Source | -199,000Source | 746,000Source | -120,000Source |
| General and Administrative Expense | — | — | — | —Source | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 224,501,000Source | 203,191,000Source | 200,581,000Source | 217,086,000Source | 204,583,000Source | 201,317,000Source | 911,981,000Source | 802,804,000Source | 624,799,000Source | 407,856,000Source |
| Cost of RevenueUSD | — | — | 31,773,000Source | 32,398,000Source | 29,122,000Source | 34,672,000Source | 27,671,000Source | 30,709,000Source | 133,225,000Source | 122,986,000Source | 96,576,000Source | 66,115,000Source |
| Selling, General and Administrative ExpenseUSD | — | — | 158,873,000Source | 130,392,000Source | 147,275,000Source | 159,521,000Source | 152,204,000Source | 144,290,000Source | 624,637,000Source | 529,607,000Source | 451,958,000Source | 320,688,000Source |
| Operating Income (Loss)USD | — | — | 9,644,000Source | 14,318,000Source | -514,000Source | -3,316,000Source | -1,118,000Source | -1,485,000Source | 50,954,000Source | 36,083,000Source | -40,271,000Source | -47,592,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -66,000Source | 118,000Source | -110,000Source | -3,498,000Source | -226,000Source | 578,000Source | -2,656,000Source | -855,000Source | -195,000Source | -49,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | 13,551,000Source | 20,326,000Source | 3,115,000Source | -2,332,000Source | 2,397,000Source | 4,159,000Source | 65,697,000Source | 58,453,000Source | -19,906,000Source | -44,268,000Source |
| Income Tax Expense (Benefit)USD | — | — | 3,619,000Source | 1,829,000Source | 2,801,000Source | 1,260,000Source | 13,691,000Source | 1,167,000Source | -79,725,000Source | 4,944,000Source | 1,247,000Source | 613,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 9,932,000Source | 18,497,000Source | 314,000Source | -3,592,000Source | -11,294,000Source | 2,992,000Source | 145,422,000Source | 53,509,000Source | -21,153,000Source | -44,881,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 0.34Source | 0.62Source | 0.01Source | -0.12Source | -0.39Source | 0.1Source | 4.95Source | 1.8Source | -0.72Source | -1.6Source |
| Earnings Per Share, DilutedUSD per share | — | — | 0.34Source | 0.6Source | 0.01Source | -0.12Source | -0.39Source | 0.1Source | 4.89Source | 1.75Source | -0.72Source | -1.6Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 29,332,376Source | 29,879,621Source | 28,835,058Source | 29,506,807Source | 28,700,525Source | 29,702,358Source | 29,368,892Source | 29,763,395Source | 29,302,154Source | 28,071,748Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 29,600,223Source | 30,633,789Source | 28,940,846Source | 29,506,807Source | 28,700,525Source | 30,311,476Source | 29,757,036Source | 30,543,274Source | 29,302,154Source | 28,071,748Source |
| Interest Expense (non-operating)USD | — | — | 11,000Source | 0Source | — | 4,000Source | — | — | 137,000Source | 22,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 9,026,000Source | 4,957,000Source | 1,247,000Source | 613,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | 3,700,000Source | 1,900,000Source | 4,600,000Source | 3,400,000Source | 5,100,000Source | 3,000,000Source | 14,000,000Source | 6,600,000Source | 2,800,000Source | 1,900,000Source |
| Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual AmountUSD | — | — | 0Source | 0Source | — | 4,000,000Source | 0Source | 0Source | 4,046,000Source | 0Source | 400,000Source | — |
| Gross ProfitUSD | — | — | 192,728,000Source | 170,793,000Source | 171,459,000Source | 182,414,000Source | 176,912,000Source | 170,608,000Source | 778,756,000Source | 679,818,000Source | 528,223,000Source | 341,741,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 1,677,000Source |
| Nonoperating Income (Expense)USD | — | — | 3,907,000Source | 6,008,000Source | — | 984,000Source | — | 5,644,000Source | 14,743,000Source | 22,370,000Source | 20,365,000Source | 3,324,000Source |
| Operating Costs and ExpensesUSD | — | — | 183,084,000Source | 156,475,000Source | 171,973,000Source | 185,730,000Source | 178,030,000Source | 172,093,000Source | 727,802,000Source | 643,735,000Source | — | — |
| Operating ExpensesUSD | — | — | — | 156,475,000Source | — | — | — | — | — | — | 568,494,000Source | 389,333,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 1,400,000Source | 1,040,000Source |
| Research and Development ExpenseUSD | — | — | 24,211,000Source | 26,083,000Source | 24,698,000Source | 26,209,000Source | 25,826,000Source | 27,803,000Source | 103,165,000Source | 114,128,000Source | 116,536,000Source | 68,645,000Source |
| General and Administrative Expense | — | — | — | —Source | — | — | — | — | — | — | — | — |
Filing attachments
insp2025-q4prereleaseex991.htm · 8-K · 2026-01-12
EX-99.1 2 insp2025-q4prereleaseex991.htm EX-99.1 Document Exhibit 99.1 Inspire Medical Systems, Inc. Announces Preliminary Unaudited Revenue Results for the Fourth Quarter and Full Year 2025 and Provides Initial 2026 Revenue Guidance Inspire Announces Appointment of Matt Osberg as Executive Vice President and Chief Financial Officer Joining the Company in the First Quarter of 2026 MINNEAPOLIS, MN - January 12, 2026 - Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”, or the “Company”…
Read attachment ↗insp2024-q4prereleaseex991.htm · 8-K · 2025-01-13
EX-99.1 2 insp2024-q4prereleaseex991.htm EX-99.1 Document Exhibit 99.1 Inspire Medical Systems, Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2024 and Provides Initial 2025 Revenue Guidance Inspire Reports Year-over-Year Revenue Growth of 25% for the Fourth Quarter and 28% for the Full Year 2024 MINNEAPOLIS, MN - January 13, 2025 - Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”, or the “Company”), a medical technology company focused on the development an…
Read attachment ↗